DIAGNOS INC (ADK.CA) Stock Price, Forecast & Analysis
Canada - TSX-V:ADK - CA2524423068 - Common Stock
ADK.CA Key Statistics, Chart & Performance
The current stock price of ADK.CA is 0.34 CAD. In the past month the price increased by 11.48%. In the past year, price increased by 3.03%.
ADK.CA Latest News, Press Relases and Analysis
ADK.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VHI.CA | VITALHUB CORP | 109.6 | 690.48M | ||
| KSI.CA | KNEAT.COM INC | N/A | 513.18M | ||
| NURS.CA | HYDREIGHT TECHNOLOGIES INC | N/A | 227.50M | ||
| KDA.CA | KDA GROUP INC | N/A | 49.58M | ||
| CHS.CA | COMPREHENSIVE HEALTHCARE SYS | N/A | 11.49M | ||
| KOVO.CA | KOVO+ HOLDINGS INC | N/A | 7.08M | ||
| AVCR.CA | AVRICORE HEALTH INC | N/A | 5.57M |
Related stock screener links
About ADK.CA
Company Profile
Diagnos, Inc. engages in the provision of healthcare technical services through the use of artificial intelligence (AI). The company is headquartered in Brossard, Quebec. The company went IPO on 2000-09-27. The company markets Computer Assisted Retinal Analysis (CARA), a software platform which assists health specialists in the detection of certain retinopathy pathologies through the computerized analysis of retina images. CARA is an in-house-hosted Web-based application that integrates fundus cameras with an image processing engine over a secure Internet connection. The CARA suite of applications allows an eye care specialist to more clearly visualize both normal retinal landmarks (optic nerve, vascular system, macula, fovea), and pathological changes (exudates, haemorrhages, micro-aneurisms, neo-vascularization). CARA is indicated for use by healthcare professionals in an adult general population in the context of a general eye-health exam.
Company Info
DIAGNOS INC
7005 Taschereau Blvd Suite 340
Brossard QUEBEC J4Z 1A7 CA
CEO: Andre Larente
Employees: 16
Phone: 14506788882
DIAGNOS INC / ADK.CA FAQ
Can you describe the business of DIAGNOS INC?
Diagnos, Inc. engages in the provision of healthcare technical services through the use of artificial intelligence (AI). The company is headquartered in Brossard, Quebec. The company went IPO on 2000-09-27. The company markets Computer Assisted Retinal Analysis (CARA), a software platform which assists health specialists in the detection of certain retinopathy pathologies through the computerized analysis of retina images. CARA is an in-house-hosted Web-based application that integrates fundus cameras with an image processing engine over a secure Internet connection. The CARA suite of applications allows an eye care specialist to more clearly visualize both normal retinal landmarks (optic nerve, vascular system, macula, fovea), and pathological changes (exudates, haemorrhages, micro-aneurisms, neo-vascularization). CARA is indicated for use by healthcare professionals in an adult general population in the context of a general eye-health exam.
What is the current price of ADK stock?
The current stock price of ADK.CA is 0.34 CAD.
Does ADK stock pay dividends?
ADK.CA does not pay a dividend.
How is the ChartMill rating for DIAGNOS INC?
ADK.CA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Which stock exchange lists ADK stock?
ADK.CA stock is listed on the TSX Venture Exchange exchange.
Should I buy ADK stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ADK.CA.
What is the next earnings date for ADK stock?
DIAGNOS INC (ADK.CA) will report earnings on 2025-11-19.
ADK.CA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ADK.CA. When comparing the yearly performance of all stocks, ADK.CA turns out to be only a medium performer in the overall market: it outperformed 64.38% of all stocks.
ADK.CA Financial Highlights
Over the last trailing twelve months ADK.CA reported a non-GAAP Earnings per Share(EPS) of -0.05. The EPS decreased by -19.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -228.11% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |